Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21632071 | 0.75 | CES2 (0.42) | CES2CES1KMT2ATRPM8RIPK1 | |
| SCHEMBL23880063 | 0.73 | CES2 (0.35) | CES2CES1KMT2ARIPK1 | |
| SCHEMBL20718842 | 0.72 | SMN1; SMN2 (0.39) | KMT2ATDP1 | |
| SCHEMBL1095475 | 0.71 | ALDH1A1 (0.37) | KMT2ATDP1 | |
| SCHEMBL1095536 | 0.70 | NOTUM (0.33) | — | |
| SCHEMBL21708737 | 0.70 | CES2 (0.33) | CES2CES1 | |
| SCHEMBL1097210 | 0.69 | USP2 (0.44) | — | |
| SCHEMBL1096585 | 0.69 | USP2 (0.41) | — | |
| SCHEMBL2935526 | 0.69 | CCR1 (0.38) | KMT2A | |
| SCHEMBL1095252 | 0.69 | CASP1 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148854-B1 | ESTERS OF 2-PHENYLALKANENITRILES AND ANTIFUNGAL COMPOSITIONS CONTAINING THEM | STOUTAMIRE DONALD WESLEY (US) | 2013-02-20 | — | — | EP | disclosed |
| US-8153688-B2 | Esters of 2-phenylalkanenitriles and antifungal compositions containing them | MCS Laboratories, Inc. (US) | 2012-04-10 | — | — | US | disclosed |
| EP-2148854-A2 | ESTERS OF 2-PHENYLALKANENITRILES AND ANTIFUNGAL COMPOSITIONS CONTAINING THEM | Stoutamire, Donald Wesley (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20100022640-A1 | ESTERS OF 2-PHENYLALKANENITRILES AND ANTIFUNGAL COMPOSITIONS CONTAINING THEM | MCS LABORATORIES INC. | 2010-01-28 | — | — | US | disclosed |
| US-7622504-B2 | Esters of 2-phenylalkanenitriles and antifungal compositions containing them | MCS Laboratories, Inc. (US) | 2009-11-24 | — | — | US | disclosed |
| WO-2008088538-A2 | ESTERS OF 2-PHENYLALKANENITRILES AND ANTIFUNGAL COMPOSITIONS CONTAINING THEM | STOUTAMIRE DONALD WESLEY (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080153905-A1 | Esters of 2-phenylalkanenitriles and antifungal compositions containing them | MCS LABORATORIES INC. | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022640-A1 | ESTERS OF 2-PHENYLALKANENITRILES AND ANTIFUNGAL COMPOSITIONS CONTAINING THEM | CYP51A1, ERG28, AKR7A2 | CES2 40/4885CES1 197/4885KMT2A 2637/4885 |
| US-20080153905-A1 | Esters of 2-phenylalkanenitriles and antifungal compositions containing them | CYP51A1, ERG28, AKR7A2 | CES2 40/4885CES1 197/4885KMT2A 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.